Artivion follows recommendation to stop proact xa clinical trial

Study was evaluating the use of apixaban in patients treated with mechanical aortic valves atlanta, sept. 23, 2022 /prnewswire/ --- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the proact xa clinical trial, a prospective, randomized, trial designed to determine if patients with an on-x mechanical aortic valve can be maintained safely and effectively on apixaban rather than on warfarin.
AORT Ratings Summary
AORT Quant Ranking